BIONIK Laboratories Corp. Annual report pursuant to Section 13 and 15(d)

WARRANTS (Tables)

12 Months Ended

Mar. 31, 2020

The following is a continuity schedule of the Company’s common share purchase warrants:


		Weighted
	Number of	Average
	Warrants	Exercise Price
		($)
Outstanding and exercisable, March 31, 2018	365,974	53.19
Issued in connection with anti-dilution provision connected warrant transaction	67,952	55.71
Issued in connection with anti-dilution provision connected warrant transaction	6,305	34.50
Issued in connection with anti-dilution provision connected warrant transaction	52,590	38.91
Expired	(204,304)	(51.85)
Outstanding and exercisable, March 31, 2019	288,517	40.27
Expired	(163,483)	(38.91)
Outstanding and exercisable, March 31, 2020	125,034	20.07

The following is a summary of common share purchase warrants outstanding as of March 31, 2020: